FDA grants Sobi’s pacritinib Fast Track status for VEXAS syndrome
AI Summary- FDA granted Sobi’s pacritinib Fast Track designation for treating VEXAS syndrome.
- Topline results from the Phase II PAXIS study are expected in 2027.
- Sobi has evaluated pacritinib in VEXAS through PAXIS since 2024.